A brief report published in Drug and Alcohol Review does something unusual: rather than discussing the molecule, it measured what was inside the vials. Researchers from the University of Queensland analysed three products sold as retatrutide that had been submitted anonymously to a testing service. The analyses were performed at an accredited laboratory, using molecular mass determination to identify the peptide and mass spectrometry for metals and impurities.
What they found
The identity was correct. In all three samples, the molecular mass matched the peptide stated on the label. These were not counterfeits containing another substance. The amount was another story: - Sample 1: 5,13 mg was measured — 51,3% of the label - Sample 2: 19,0 mg was measured — 190% of the label - Sample 3: 16,5 mg was measured — 165% of the label In the authors' words, the content ranged from approximately half to almost twice the labelled amount. For heavy metals, the picture was reassuring: lead at 0,7 mg/kg, equivalent to 0,14% of the permitted exposure limit, with copper and zinc at acceptable levels.
Why it matters
The finding is not adulteration — it is inconsistency. A product with the correct contents but the wrong amount passes every cursory check and still is not what it claims to be. The authors state it clearly: inaccurate content poses a risk independent of counterfeiting. Two vials from the same shelf, with the same label, may differ from each other by three and a half times.
The limitations of this report
Honesty is needed here, because the finding is striking and easy to overinterpret. Three samples are not a representative sample of the market. This is a brief report, not a surveillance study. It does not show what proportion of products worldwide deviates from the label. The samples were submitted anonymously and voluntarily to a testing service. Someone may send a sample precisely because they have doubts — which means the sample may not be random. And it concerns the Australian market during a specific period.
What we take from it
The identity of a peptide and its amount are two different questions, and the second can only be answered through analytical documentation for each batch. That is why certificates of analysis exist — and why it matters to ask whether they are available rather than assume it.
Source
Piatkowski T., Craven A., Cornell S., Ferris J. Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia. Drug and Alcohol Review, 2026;45(6):e70231. DOI: 10.1111/dar.70231 — https://doi.org/10.1111/dar.70231 Full text freely available. Retrieved via PubMed. Retatrutide has not been approved by the FDA or EMA. Products are supplied exclusively for research use.